

**PHARMACY PRIOR AUTHORIZATION REQUEST FORM**

**OPHTHALMIC INJECTIONS**

Avastin<sup>®</sup>, Beovu<sup>®</sup>, Byooviz<sup>™</sup>, Cimerli<sup>™</sup>, Eylea<sup>®</sup>, Lucentis<sup>®</sup>, Macugen<sup>®</sup>, Vabysmo<sup>™</sup>

**For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department at 801-213-1547.**

**Failure to submit clinical documentation to support this request will result in a dismissal of the request.**

If you have medical pharmacy prior authorization questions, please call for assistance: Individual Exchange: 833-981-0214, Commercial Groups: 833-981-0213, MHC: 844-262-1560

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:	HCPCS Code:	

**Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.**

**Preferred:**  Avastin<sup>®</sup> (bevacizumab) prior authorization not required,  Byooviz<sup>™</sup> (ranibizumab-nuna),  Cimerli<sup>™</sup> (ranibizumab-eqrn),  Eylea<sup>®</sup> (aflibercept)

**Non-preferred:**  Beovu<sup>®</sup> (brolucizumab-dblI),  Lucentis<sup>®</sup> (ranibizumab),  Macugen<sup>®</sup> (pegaptanib),  Susvimo<sup>™</sup> (ranibizumab implant),  Syforve<sup>™</sup> (pegcetacoplan),  Vabysmo<sup>™</sup> (faricimab-svoa)

\*preferred first line, \*\*preferred second line, \*\*\*preferred third line

Dosing/Frequency: \_\_\_\_\_

**If the request is for reauthorization, proceed to reauthorization section**

Questions	Yes	No	Comments/Notes
1. Is the member 18 years of age or older?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Is the requesting provider an ophthalmologist or in consultation with one?	<input type="checkbox"/>	<input type="checkbox"/>	
3. Does the member have a diagnosis of diabetic macular edema (DME), diabetic retinopathy (DR) in patients with DME, age-related macular edema (AMD), myopic choroidal neovascularization (mCNV), or macular edema following a retinal vein occlusion (RVO)?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
4. Does the member have a baseline visual acuity score?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
5. For Beovu <sup>®</sup> , does documentation show a trial and failure of Avastin <sup>®</sup> and Eylea <sup>®</sup> ?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
6. For Byooviz <sup>™</sup> , does documentation show a diagnosis of AMD, RVO or mCNV and a trial and failure of Avastin <sup>®</sup> and Eylea <sup>®</sup> ?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>

**Confidentiality Notice**

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.

7. For Cimerli™, does documentation show a diagnosis of DME or DR and trial and failure of Avastin® and Eylea®?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
8. For Eylea®, does documentation show a trial and failure of Avastin®?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
9. For Lucentis®, does documentation show a trial and failure of Avastin®, Byooviz™ or Cimerli™, and Eylea®?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
10. For Macugen®, does documentation show a trial and failure of Avastin®, Byooviz™ or Cimerli™, and Eylea®?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
11. For Vabysmo™, does documentation show a trial and failure of Avastin®, Byooviz™ or Cimerli™, and Eylea®?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
<b>REAUTHORIZATION</b>			
1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Do updated clinical notes show a positive response to therapy and a continued medical necessity?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
<b>What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.</b>			
Additional information:			
Physician's Signature:			

**\*\* Failure to submit clinical documentation to support this request will result in a dismissal of the request.\*\***

Policy: PHARM-M005  
 Origination Date: 03/30/2016  
 Reviewed/Revised Date: 03/15/2023  
 Next Review Date: 03/15/2024  
 Current Effective Date: 04/01/2023

**Confidentiality Notice**

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.